Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06780670 · ClinicalTrials.gov registry record · Phase 2

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

A Phase 2 study of Prostate Cancer, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
443
Enrollment target
20
Study locations

NCT06780670 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 443 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06780670, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
443 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Investigators choice of SoC
  • DRUG AAA817

Study Locations (20)

São Paulo

  • Novartis Investigative Site - São Paulo
  • Novartis Investigative Site - São Paulo

Hubei

  • Novartis Investigative Site - Wuhan
  • Novartis Investigative Site - Wuhan

Jiangsu

  • Novartis Investigative Site - Nanjing
  • Novartis Investigative Site - Nanjing

California

  • VA Greater LA Healthcare System - Los Angeles

Georgia

  • University Cancer and Blood Center LLC - Athens

Indiana

  • Indiana University - Indianapolis

Kansas

  • University of Kansas Hospital - Kansas City

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 443 participants
Start Date 2025-02-27
Est. Completion 2033-07-19
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06780670

The ClinicalTrials.gov registry entry for NCT06780670 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 443 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (27% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Investigators choice of SoC is the first listed.

NCT06780670 reports 20 study locations spanning 17 distinct geographic areas - top geographies include São Paulo, Hubei, Jiangsu.

Frequently Asked Questions

What is clinical trial NCT06780670 about?

NCT06780670 is a clinical study titled "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy". This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational t...

What is the current status of trial NCT06780670?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 443 participants. The study started on 2025-02-27. Estimated completion is 2033-07-19.

What conditions does trial NCT06780670 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06780670?

The interventions under investigation include: Investigators choice of SoC (DRUG), AAA817 (DRUG).

Who is sponsoring clinical trial NCT06780670?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06780670 being conducted?

This trial has 20 study locations across California, Georgia, Indiana, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.